Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

A phase 1/2 study of EP0062 (vosilasarm), a first-in-class oral selective androgen receptor modulator (SARM), in combination with standard-of-care endocrine therapy +/- targeted therapies in patients with advanced or metastatic AR+/ER+/HER2− breast cancer.

Rafael Grochot, Hyo S. Han, Meritxell Bellet et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1151

TPS1151 Background: EP0062 (vosilasarm), a first-in-class, oral, non-steroidal, Selective Androgen Receptor Modulator (SAR...

Age-related efficacy of antibody-drug conjugates in solid tumors: A meta-analysis.

Mariana Macambira Noronha, Luiz F. Costa De Almeida, Valbert Filho et al. Jun 01, 2026 pp. 1664-1664 10.1200/jco.2026.44.16_suppl.1664

1664 Background: Antibody–drug conjugates (ADC) have revolutionized cancer therapeutics, with various ADC improving clinic...

Dynamic circulating tumor DNA profiling for prediction of long-term clinical benefit in pMMR locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy plus sintilimab.

Xiaobin Zheng, Huashan Liu, Zhihong Zhang et al. Jun 01, 2026 pp. 3590-3590 10.1200/jco.2026.44.16_suppl.3590

3590 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1 have significantly improved outcomes in locally advanc...

Clinicopathologic features and survival outcomes of HER2-low versus HER2-negative (IHC 0) breast cancer in real-world practice.

Maria Paula Uchima-Vera, Manuela Estrada, Maria Alejandra Gomez-Gutierrez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23417

e23417 Background: With the advent of antibody–drug conjugates, HER2-low disease emerged as a clinically relevant subgroup...

Examining the tumor microbiology and microenvironment of patients with triple-negative inflammatory breast cancer receiving KEYNOTE-522.

Azadeh Nasrazadani, Bora Lim, Angela Alexander et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12594

e12594 Background: Patients with Stage III triple negative (TN) inflammatory breast cancer (IBC) are treated based on stan...

Phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated, unresectable, or metastatic colorectal cancer (ROSETTA CRC-203).

Tiago Biachi de Castria, Ian Chau, Elena Elez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3672

TPS3672 Background: Microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer (mCRC) demonstrated limi...

A phase I, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activities of GenSci139 in patients with solid tumors.

Jinming Yu, Yuping Sun, Tongsen Zheng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps4638

TPS4638 Background: HER2 and EGFR are frequently co-expressed in solid tumors. Bispecific targeting of these receptors can...

Construction and clinical application of a bundled nursing care program for PICC management in patients with nasopharyngeal carcinoma.

Jia Cao, Guoyan Cheng, Hualing Feng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13612

e13612 Background: Purpose To develop a bundled nursing care program for peripherally inserted central catheter (PICC) man...

Comparative effectiveness of adjuvant chemotherapy on survival in node-positive (N2/N3), stage III ER+/HER2− invasive lobular breast cancer (ILC) versus invasive ductal cancer (IDC).

Sumeet K. Yadav, Tanya L. Hoskin, Judy Caroline Boughey et al. Jun 01, 2026 pp. 545-545 10.1200/jco.2026.44.16_suppl.545

545 Background: ILC is characterized by loss of E-cadherin expression, with distinct biological and clinical features, and...

Antigen presentation suppression as a hallmark of immune evasion and poor outcomes in small cell lung cancer.

Triparna Sen, Elisa Gobbini, Vrinda Jethalia et al. Jun 01, 2026 pp. 8084-8084 10.1200/jco.2026.44.16_suppl.8084

8084 Background: Antigen-presenting machinery (APM) is critical for tumor immune recognition. The loss of APM promotes imm...

A phase 3 study of sacituzumab govitecan in patients with previously treated extensive-stage small cell lung cancer.

Afshin Dowlati, Myung-Ju Ahn, Alan Arrieira Azambuja et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8137

TPS8137 Background: Treatment options for extensive-stage small cell lung cancer (ES-SCLC) that has progressed after plati...

PTCy, abatacept, and short course of tacrolimus (CAST) therapy in GVHD prevention in mismatch-unrelated donors.

James Behrmann, Jingmei Hsu, Oscar Lahoud et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18568

e18568 Background: Hematopoietic stem cell transplant (HSCT) remains a potentially curative therapy for a wide range of he...

Primary results from the triple-negative cohort of TBCRC-053 (P-RAD): A randomized trial of no, low, or high dose preoperative radiation with pembrolizumab and chemotherapy in node-positive breast cancer.

Alice Yoosun Ho, Laura Spring, Faeze Gharibpoor et al. Jun 01, 2026 pp. 1011-1011 10.1200/jco.2026.44.16_suppl.1011

1011 Background: Approximately one-quarter of patients with node-positive, triple-negative breast cancer (TNBC) did not ex...

A randomized non-inferiority trial of an eHealth delivery alternative for cancer genetic testing for hereditary cancer (eREACH2).

Kimberley T. Lee, Brian Lee Egleston, Dominique Fetzer et al. Jun 01, 2026 pp. 10510-10510 10.1200/jco.2026.44.16_suppl.10510

10510 Background: Germline cancer genetic testing is a standard evidence-based practice, with established risk reduction a...

Bridging the gap between knowledge, attitudes, and practice regarding physical activity and exercise among Greek medical oncologists.

Evangelos Voulgaris, Athanasios Z. Jamurtas, Antonis Stavropoulos-Kalinoglou et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23141

e23141 Background: Physical activity and exercise (PAE) are core components of evidence-based cancer care. However, eviden...

Ablation of oligo-residual disease to prolong progression-free survival in <i>EGFR</i> -mutant advanced NSCLC patients treated with third-generation EGFR-TKIs.

Jizhong Yin, Shuo Yang, Menghang Yang et al. Jun 01, 2026 pp. 8633-8633 10.1200/jco.2026.44.16_suppl.8633

8633 Background: Combination of EGFR-TKIs with chemotherapy or amivantamab have become the standard of care for EGFR-mutan...

Node-sparing modified short-course radiotherapy combined with capecitabine and PD-1/CTLA-4 for MSS early, middle, and low rectal cancer (mRCAT-E): An open-label, single-arm, prospective multicenter clinical trial.

Zhangfa Song, Bingjun Bai, Weifeng Lao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3687

TPS3687 Background: The standard treatment for early-stage rectal cancer is radical resection. For patients' organ preserv...

Environmental exposure and prevalence of papillary thyroid cancer in West Virginia: An ecological analysis of per and polyfluoroalkyl substances (PFAS)–impacted regions.

Sanjana Nethagani, Hiba Khan, Danielle DeCicco et al. Jun 01, 2026 pp. 6073-6073 10.1200/jco.2026.44.16_suppl.6073

6073 Background: Per- and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants with widespread expo...

Real-world outcomes in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab deruxtecan (T-DXd) based on HER2 expression.

Maria Baez, Shalini Reddy Vemuru, Tarrant McPherson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13013

e13013 Background: T-DXd is an effective HER2-directed antibody-drug conjugate (ADC) approved for HER2-positive (IHC 3+ or...

Enhancing supportive care in malignant bowel obstruction: A QI project using virtual dietitian-led low-fiber diet education.

Bojan Macanovic, Vikas Garg, Nazlin Jivraj et al. Jun 01, 2026 pp. 12068-12068 10.1200/jco.2026.44.16_suppl.12068

12068 Background: Malignant bowel obstruction (MBO) is a frequent, debilitating complication in patients with gynecologic...

Characteristics associated with five-star online reviews of oncologists.

Anthony Yeung, Mateo Alzate Aguirre, Samuel Black et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13533

e13533 Background: Patient satisfaction has become an increasingly important component of healthcare quality, leading to g...

Post-ARPI sequencing in mCRPC: A propensity-matched real-world comparison of <sup>177</sup> Lu-PSMA-617 versus docetaxel for early clinical outcomes.

Sooraj Srirangadhamu Gopu, Kanishka Uttam Chandani, Jatin Thukral et al. Jun 01, 2026 pp. 5079-5079 10.1200/jco.2026.44.16_suppl.5079

5079 Background: Treatment sequencing in metastatic castration-resistant prostate cancer (mCRPC) after ADT and ARPI exposu...

Correlation of tumor-naive methylation-based preoperative ctDNA testing with pathologic upstaging and occult metastasis in early-stage solid tumors.

Xiangnan Li, Jiandong Tai, Jiaqi Liu et al. Jun 01, 2026 pp. 1616-1616 10.1200/jco.2026.44.16_suppl.1616

1616 Background: The TNM staging system serves as the cornerstone for most solid tumor treatment strategies. However, preo...

Mapping the association between federal AI investment and clinical validation in oncology: A multi-source ecosystem analysis.

Tuan Vinh, Julie Ying Zhang, Anvi Anand et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13663

e13663 Background: Artificial intelligence (AI) in oncology, including computer vision and radiomics, has expanded rapidly...

Cell proliferation, immune cell infiltration, and survival outcomes in sarcomas with high cancer-associated fibroblast expression.

Olivia Martin, Kei Kawashima, Masanori Oshi et al. Jun 01, 2026 pp. 11541-11541 10.1200/jco.2026.44.16_suppl.11541

11541 Background: Cancer-associated fibroblasts (CAFs) play an integral role in the tumor microenvironment and have been l...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page